MedTrace Logo

The Role of Leptin Receptors in NASH

NCT00583999 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2017-05-30

No results posted yet for this study

Summary

NAFLD is a spectrum of liver diseases associated with varying degrees of hepatic steatosis, inflammation, and in some cases, fibrosis. NAFLD is a common observation in all demographics, but the prevalence of NAFLD and nonalcoholic steatohepatitis (NASH) is especially high in the morbidly obese population. Leptin is a cytokine that is encoded by the ob gene and primarily secreted by adipose tissue. The production of serum leptin increases with progressive obesity. Because of this observation, there has been significant interest in potential role of leptin in NAFLD.

Our hypothesis is that we will find increased hepatic leptin and leptin receptor expression as the degree of hepatic injury worsens in NAFLD.

Conditions

Interventions

OTHER

no interventions, only regular blood-draw

No interventions, only regular blood-draw (liver biopsy obtained per routine during the surgery)

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Natalie Torok, MD · UC Davis

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00583999 on ClinicalTrials.gov